Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation from Unrelated Donors

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 5, 2008, Pages 531-537

  Furlong, Terry ^a   Kiem, Hans Peter ^a   Appelbaum, Frederick R ^a   Carpenter, Paul A ^a   Deeg, H Joachim ^a   Doney, Kristine ^a   Flowers, Mary E D ^a   Mielcarek, Marco ^a   Nash, Richard A ^a   Storb, Rainer ^a   Martin, Paul J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Graft versus host disease; Hematopoietic cell transplantation; Sirolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; RAPAMYCIN; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DONOR; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; REFRACTORY ANEMIA WITH EXCESS BLASTS; RHABDOMYOLYSIS; SIDE EFFECT; STEM CELL MOBILIZATION; TREATMENT PLANNING; WHOLE BODY RADIATION;

CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; SIROLIMUS; TACROLIMUS;

EID: 41849148993     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.02.009     Document Type: Article

References (26)

1. Sullivan K.M. Graft-versus-host disease. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation. 3rd Ed. (2004), Blackwell Publishing Ltd., Oxford, UK 635-664
2. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
3. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
4. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
5. Przepiorka D., Khouri I., Ippoliti C., et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 24 (1999) 763-768
6. Uberti J.P., Ayash L., Braun T., Reynolds C., Silver S., and Ratanatharathorn V. Tacrolimus as monotherapy or combined minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term effects. Bone Marrow Transplant 34 (2004) 425-431
7. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
8. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338 (1998) 962-968
9. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328 (1993) 593-602
10. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 10 (2004) 320-327
11. Dumont F.J., Staruch M.J., Koprak S.L., Melino M.R., and Sigal N.H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144 (1990) 251-258
12. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 (2003) 7S-14S
13. Morris R.E. Rapamycin: FK506's fraternal twin or distant cousin?. Immunol Today 12 (1991) 137-140
14. Groth C.G., Backman L., Morales J.M., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67 (1999) 1036-1042
15. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet 356 (2000) 194-202
16. Kahan B.D., Knight R., Schoenberg J., et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 35 (2003) 25S-34S
17. Trotter J.F. Sirolimus in liver transplantation. Transplant Proc 35 (2003) 193S-200S
18. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72 (2001) 1924-1929
19. Couriel D.R., Saliba R., Escalon M.P., et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130 (2005) 409-417
20. Johnston L.J., Brown J., Shizuru J.A., et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 47-55
21. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 328-336
22. Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102 (2003) 1601-1605
23. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109 (2007) 3108-3114
24. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
25. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 (2005) 945-955
26. Saliba R.M., DeLima M., Giralt S., et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109 (2007) 2751-2758